Kim Emily Y, Walker Brooks D, Hopkins Nikolas S, Fowler Samuel, Jerkins Brian M, Kanner Elliott M, Wright Claire L
Department of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, TN 38103, USA.
J Clin Med. 2024 Sep 27;13(19):5753. doi: 10.3390/jcm13195753.
: This study aims to compare micropulse transscleral cyclophotocoagulation (MP-TSCPC) laser parameters and determine the optimal laser setting. : A retrospective study was performed on 351 eyes from patients who underwent MP-TSCPC at four power settings (1500 mW, 2000 mW, 2250 mW, and 2500 mW) from June 2018 to December 2021. The primary measurements of the efficacy of MP-TSCPC were the degree of intraocular pressure (IOP) reduction and the number of glaucoma medication reductions. The rate of hypotony was obtained to assess the safety of MP-TSCPC. At 1500, 2000, and 2500 mW, the mean IOP reduction at each visit was statistically significant compared to the baseline, and at 2250 mW, the mean IOP was only significantly different at 18 months ( < 0.05). The change in the number of medications with 2000 mW has shown significance at 1 and 3 months from the baseline; with 2500 mW, statistical significance was shown at 3, 6, 12, and 18 months ( < 0.05) compared to the baseline. Mean IOP reductions (%) were greater in 2000 mW than in 1500 mW at 1 week, 1 month, and 3 months and were greater in 2500 than in 1500 mW at 1 week ( < 0.05). There was no significance for mean IOP reductions at 6, 12, and 18 months across all powers. Only two occurrences of hypotony were reported. : MP-TSCPC at 1500 mW, 2000 mW, and 2500 mW is a safe and effective treatment for IOP reduction. MP-TSCPC at 2250 mW is safe but may show delayed effectiveness in IOP reduction. In the long term, no one specific power setting was found to be superior for IOP reduction.
本研究旨在比较微脉冲经巩膜睫状体光凝术（MP - TSCPC）的激光参数并确定最佳激光设置。对2018年6月至2021年12月期间在四种功率设置（1500毫瓦、2000毫瓦、2250毫瓦和2500毫瓦）下接受MP - TSCPC治疗的患者的351只眼睛进行了回顾性研究。MP - TSCPC疗效的主要测量指标是眼压（IOP）降低程度和青光眼药物使用减少的数量。通过获得低眼压发生率来评估MP - TSCPC的安全性。在1500毫瓦、2000毫瓦和2500毫瓦时，每次随访时的平均IOP降低与基线相比具有统计学意义，而在2250毫瓦时，平均IOP仅在18个月时具有显著差异（<0.05）。2000毫瓦时药物数量的变化在基线后1个月和3个月时显示出显著性；2500毫瓦时，与基线相比，在3个月、6个月、12个月和18个月时具有统计学意义（<0.05）。在1周、1个月和3个月时，2000毫瓦时的平均IOP降低百分比大于1500毫瓦时，在1周时，2500毫瓦时大于1500毫瓦时（<0.05）。在所有功率下，6个月、12个月和18个月时的平均IOP降低无显著性差异。仅报告了两例低眼压情况。1500毫瓦、2000毫瓦和2500毫瓦的MP - TSCPC是降低IOP的安全有效治疗方法。2250毫瓦的MP - TSCPC是安全的，但在降低IOP方面可能显示出延迟的有效性。从长期来看，未发现一种特定的功率设置在降低IOP方面具有优越性。
